Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24413260
DOI
10.1097/qad.0000000000000112
PII: 00002030-201401020-00002
Knihovny.cz E-resources
- MeSH
- ATP Binding Cassette Transporter, Subfamily G, Member 2 MeSH
- ATP-Binding Cassette Transporters metabolism MeSH
- Adenine analogs & derivatives metabolism pharmacokinetics MeSH
- Cell Line MeSH
- Rats MeSH
- Anti-HIV Agents metabolism pharmacokinetics MeSH
- Humans MeSH
- Neoplasm Proteins metabolism MeSH
- Organophosphonates metabolism pharmacokinetics MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Rats, Wistar MeSH
- Multidrug Resistance-Associated Protein 2 MeSH
- Multidrug Resistance-Associated Proteins metabolism MeSH
- Tenofovir MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ATP Binding Cassette Transporter, Subfamily G, Member 2 MeSH
- ATP-Binding Cassette Transporters MeSH
- ABCB1 protein, human MeSH Browser
- ABCC2 protein, human MeSH Browser
- ABCG2 protein, human MeSH Browser
- Adenine MeSH
- Anti-HIV Agents MeSH
- Neoplasm Proteins MeSH
- Organophosphonates MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Multidrug Resistance-Associated Protein 2 MeSH
- Multidrug Resistance-Associated Proteins MeSH
- Tenofovir MeSH
OBJECTIVE AND DESIGN: Tenofovir (TFV) is used in pregnant women as a part of combination antiretroviral treatment to prevent mother-to-child transmission of HIV infection. We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2). We employed in-vitro cell-based assays and in-situ animal model to assess possible role of the efflux transporters in transplacental pharmacokinetics of TFV and TDF. METHODS: In-vitro transport assays were performed in MDCKII cells transduced with human ABCB1, ABCG2 or ABCC2. To quantify the effect of these transporters on TFV/TDF transplacental passage, we employed the in-situ model of dually perfused rat term placenta in open and closed setup. RESULTS: In-vitro assays revealed that TDF is a dual substrate of ABCB1 and ABCG2 but not of ABCC2. In contrast, TFV transport was not influenced by any of these transporters. Applying concentration-dependent studies and selective inhibitors, we further confirmed these findings in situ on the organ level; both ABCB1 and ABCG2 limited mother-to-fetus transfer of TDF whereas TFV transplacental passage was not affected by these ABC transporters. CONCLUSION: We propose limited mother-to-fetus transport of both TFV and TDF. While placental transport of TFV is restricted passively, by physical-chemical properties of the molecule, mother-to-fetus passage of TDF is actively hindered by placental ABCB1 and ABCG2 transporters, pumping this compound from trophoblast back to maternal circulation.
References provided by Crossref.org
Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine